<div><div></div><div><span><ul><li><span>According to estimates from 14 analysts, Pharvaris N.V. stock's average price target has fallen from $46.85 to $46.6, with forecasts ranging from $30.9 to $74.02 per share</span></li><li><span>Based on the May 12 closing price, the updated target implies approximately 49% potential upside</span></li><li><span>Consensus rating remains at “Buy” across 14 covering analysts, with 13 Buys, 1 Holds and 0 Sells</span></li></ul><p><span>Explore more price target data and ratings for Pharvaris N.V. on the </span><span>, and track all previous and future analyst recommendations for Pharvaris N.V. in the dedicated </span>News Flow<span>.</span></p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.</span></div></section></span></div></div>

PHVS

SBIO

<p>Pharvaris N.V.'s 12-month stock price target has been reduced from $46.85 to $46.6, suggesting a potential upside of 49% based on the May 12 closing price. The consensus rating remains a "Buy" from 14 analysts, with 13 recommending buys and 1 hold. Price forecasts range from $30.9 to $74.02 per share.</p>

TradingView

Pharvaris BV

ALPS Medical Breakthrough

VG Health

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

SPDR S&P Biotech

Ark Genomic Revolution ETF

Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.6, Implies 49% Upside